Loading data for CERS — first visit, this takes a few seconds.

Preisalarm

Cerus Corporation (CERS)

NasdaqGM: CERS · Echtzeitkurs · USD

2.81

+0.02 (0.72%)

Zum Schluss: Aug 25, 2026, 8:00 PM

2.80

+2.94%

Vorbörslich: 8:04 AM

Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.

0.72% (1D)

Keine Daten verfügbar

Geld	2.09
Marktkapitalisierung	548.15 Mio
Umsatz (TTM)	221.55 Mio
Nettogewinn (TTM)	-6.78 Mio
	1.77
	-0.03
	n/a
	-544
KBV (TTM)	7.82
KUV (TTM)	2.47
Termin Quartalszahlen	Nov 6, 2025

Brief	2.76
Volumen	2,489,755
Ø Vol. (20D)	2,756,262
Eröffnung	2.81
Vortagesschluss	2.79
Tagesspanne	2.78 - 2.87
52-Wk Range	1.17 - 3.47
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and...

[Mehr lesen]

Branche Medical Devices

Sektor Healthcare

IPO Datum Jan 31, 1997

Mitarbeiter 261

Börse NasdaqGM

Tickersymbol CERS

Website https://www.cerus.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Cerus 206.13 Mio, ein Anstieg von 14.35% im Vergleich zum Vorjahr (180.27 Mio). Der Gewinn lag bei -15.63 Mio, ein Rückgang von -25.29 %.

Finanzberichte

Gewinnüberraschung

Cerus hat die Quartalszahlen am Jul 30, 2026 veröffentlicht:

Umsatz von $57.44 Mio verfehlt die Erwartungen um $0, mit 9.53% Wachstum im Jahresvergleich.
EPS von -0.01 verfehlt die Erwartungen um 0.00, mit 75.00% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Cerus Corporation wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 6, 2025, nach Börsenschluss.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 3 Wochen · MarketBeat

Cerus Q2 Earnings Call Highlights

Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety produc...

vor 2 Monaten · Insider Monkey

Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M

Cerus Corporation (NASDAQ:CERS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providin...

vor 2 Monaten · Zacks

Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?

Here is how BrightSpring Health Services, Inc. (BTSG) and Cerus (CERS) have performed compared to their sector so far this year.

vor 3 Monaten · Insider Monkey

Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG

Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. T...

vor 3 Monaten · Simply Wall St.

3 Penny Stocks With Market Caps Under $500M And Promising Growth

Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying...

Seite 1 von 2

Cerus Corporation (CERS)